Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors

NCT06457997 is registered in ClinicalTrials.gov with Pheon Therapeutics as lead sponsor.

NCT NCT06457997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06457997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Lead sponsor
Pheon Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
July 1, 2024
Completion date
September 11, 2025
Enrollment
26 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced solid tumor, cervical cancer, colon cancer, endometrial cancer, lung cancer, ovarian cancer